top of page

Somatolynk, Inc. is a drug discovery and development company (incorporated in Delaware, 2017) focused on therapeutics targeting somatostatin receptors. Our program is dedicated to the advancement of orally bioavailable small-molecule somatostatin receptor medications with applications for Alzheimer's, neuropsychiatric disorders, epilepsy, and inflammatory conditions. ​

Team

bottom of page